Literature DB >> 10441098

Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes.

P Aukrust1, F Müller, T Ueland, T Berget, E Aaser, A Brunsvig, N O Solum, K Forfang, S S Frøland, L Gullestad.   

Abstract

BACKGROUND: The CD40 ligand (CD40L) on activated T cells and platelets may be activating matrix metalloproteinases, inducing procoagulant activity, and be involved in the pathogenesis of acute coronary syndromes by promoting plaque rupture in atheroma. METHODS AND
RESULTS: To study the role of CD40L-CD40 interaction in coronary disease, we analyzed levels of soluble (s) and membrane-bound CD40L in the peripheral blood from 29 patients with stable angina, 26 with unstable angina, and 19 controls. Our main findings follow. (1) Patients with unstable angina had significantly raised serum levels of sCD40L when compared with patients with stable angina and controls. (2) Platelets could release large amounts of sCD40L when stimulated ex vivo with the thrombin receptor-agonist peptide SFLLRN in both patients and controls. (3) Platelets in patients with unstable angina were characterized ex vivo by decreased intracellular levels and decreased SFLLRN-stimulated release of sCD40L, which may possibly represent a higher percentage of degranulated platelets in these patients. (4) T cells in patients with unstable angina had enhanced surface expression of CD40L and increased release of sCD40L on anti-CD3/anti-CD28 stimulation in vitro when compared with patients with stable angina and controls. (5) Recombinant CD40L and serum from patients with unstable angina who had high sCD40L levels induced enhanced release of monocyte chemoattractant peptide-1 from mononuclear cells, a CC-chemokine involved in the pathogenesis of atherosclerosis.
CONCLUSIONS: This first demonstration of enhanced levels of soluble and membrane-bound forms of CD40L in angina patients, with particularly high levels in patients with unstable angina, suggests that CD40L-CD40 interaction may play a pathogenic role in both the long-term atherosclerotic process and in the triggering and propagation of acute coronary syndromes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10441098     DOI: 10.1161/01.cir.100.6.614

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  72 in total

1.  Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system.

Authors:  R P Phipps
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

Review 2.  Vascular inflammation as a therapeutic target for prevention of cardiovascular disease.

Authors:  Luther T Clark
Journal:  Curr Atheroscler Rep       Date:  2002-03       Impact factor: 5.113

Review 3.  Inflammatory and oxidative markers in atherosclerosis: relationship to outcome.

Authors:  Mehdi H Shishehbor; Stanley L Hazen
Journal:  Curr Atheroscler Rep       Date:  2004-05       Impact factor: 5.113

4.  Osteoprotegerin is not associated with angiographic coronary calcification.

Authors:  Prospero B Gogo; David J Schneider; Edward F Terrien; Burton E Sobel; Harold L Dauerman
Journal:  J Thromb Thrombolysis       Date:  2006-12       Impact factor: 2.300

5.  Association of soluble CD40 ligand with carotid atherosclerosis in Japanese type 1 diabetic patients.

Authors:  N Katakami; H Kaneto; M Matsuhisa; T Miyatsuka; K Sakamoto; D Kawamori; K Yoshiuchi; Y Nakamura; K Kato; K Yamamoto; K Kosugi; M Hori; Y Yamasaki
Journal:  Diabetologia       Date:  2006-05-12       Impact factor: 10.122

Review 6.  Using biomarkers to assess risk and consider treatment strategies in non-ST-segment elevation acute coronary syndromes.

Authors:  Ankie Amos; L Kristin Newby
Journal:  Curr Cardiol Rep       Date:  2005-07       Impact factor: 2.931

Review 7.  In stent restenosis: bane of the stent era.

Authors:  A K Mitra; D K Agrawal
Journal:  J Clin Pathol       Date:  2006-03       Impact factor: 3.411

Review 8.  Proinflammatory, immunomodulating, and prothrombotic properties of anemia and red blood cell transfusions.

Authors:  Katie M Twomley; Sunil V Rao; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2006-04       Impact factor: 2.300

9.  Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients.

Authors:  S Danese; J A Katz; S Saibeni; A Papa; A Gasbarrini; M Vecchi; C Fiocchi
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

10.  Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling.

Authors:  K S Srinivasa Prasad; Patrick Andre; Ming He; Ming Bao; Jeanne Manganello; David R Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.